Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05012462 · ClinicalTrials.gov registry record · NA
Clinical Evaluation of the CM-1500 During Apheresis Blood Donation
A NA study of Fluid Loss, sponsored by Zynex Monitoring Solutions.
- Completed
- Registry status
- NA
- Development phase
- 77
- Enrollment target
- 1
- Study location
NCT05012462: Completed NA study of Fluid Loss, sponsored by Zynex Monitoring Solutions.
NCT05012462 is a NA study of Fluid Loss that has completed, run by Zynex Monitoring Solutions. The registered enrollment target is 77 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05012462, a NA study of Fluid Loss, has completed, sponsored by Zynex Monitoring Solutions.
- COMPLETED
- Registry status
- NA
- Development phase
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is a prospective, single-arm, non-randomized, non-blinded, non-controlled, non-significant risk, single center study enrolling up to 200 healthy adult subjects consented to undergo an apheresis donation procedure. Subjects will be connected to the Zynex Cardiac Monitor, Model 1500 (CM-1500) to characterize changes in the relative index during an apheresis donation procedure.
Primary Outcome
The objective of the study is to characterize changes in the Relative Index (RI) as a representation of its associated parameters during apheresis. This was measured by averaging the RI values after the procedure. Changes in parameters from their baseline can be used as an indicator of potential change in fluid status. This change may be reflected in the RI since it is a summated value (weighted summation of percent change) combining the changes of the parameters into a single value. In the case
Conditions Studied
Interventions
- DEVICE CM-1500
- DEVICE CM-1600
Study Locations (1)
Colorado
- Vitalant Blood Donation - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2022-12-20 |
| Phase | NA |
What the finished NCT05012462 record still lists
NCT05012462 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Fluid Loss appearing as the primary indexed condition, and to 2 interventions - of which CM-1500 is the first listed.
NCT05012462 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT05012462 about?
NCT05012462 is a clinical study titled "Clinical Evaluation of the CM-1500 During Apheresis Blood Donation". The study is a prospective, single-arm, non-randomized, non-blinded, non-controlled, non-significant risk, single center study enrolling up to 200 healthy adult subjects consented to undergo an apheresis donation procedure. Subjects will be connected to the Zynex Cardiac Monitor, Model 1500 (CM-1500...
What is the current status of trial NCT05012462?
This trial is currently completed. It is a NA study. The enrollment target is 77 participants. The study started on 2021-09-20. Estimated completion is 2022-12-20.
What conditions does trial NCT05012462 study?
This clinical trial studies the following conditions: Fluid Loss.
What interventions are being tested in trial NCT05012462?
The interventions under investigation include: CM-1500 (DEVICE), CM-1600 (DEVICE).
Who is sponsoring clinical trial NCT05012462?
This trial is sponsored by Zynex Monitoring Solutions, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05012462 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05012462's enrollment target sits among peer trials
77 1062nd of 2000 higher than 939 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI